Evolus, Inc. (EOLS) compared with its closest peers (VSTM, ALT, AQST, STTK, SPRY). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Verastem, Inc. (VSTM) | $605.45M | -2.6 |
| Altimmune, Inc. (ALT) | $602.87M | -3.6 |
| Aquestive Therapeutics, Inc. (AQST) | $583.63M | -8.4 |
| Shattuck Labs, Inc. (STTK) | $578.55M | -5.2 |
| ARS Pharmaceuticals, Inc. (SPRY) | $546.17M | -6.7 |
| Ovid Therapeutics Inc. (OVID) | $545.86M | — |
| Sagimet Biosciences Inc. (SGMT) | $544.42M | -3.7 |
| NovaBridge Biosciences (NBP) | $530.76M | -18.9 |
| Prelude Therapeutics Incorporated (PRLD) | $528.30M | -2.2 |
| MapLight Therapeutics, Inc. (MPLT) | $523.89M | -0.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
EOLS overview · EOLS earnings · EOLS financials · EOLS KPIs · EOLS investor relations · EOLS ownership · EOLS filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.